Sponsor content
217 result(s) found, displaying 21 to 30
-
Australian public assessment report (AusPar)Gazyva (obinutuzumab) was approved as a pre-treatment to reduce the risk of cytokine release syndrome (CRS) induced by glofitamab.
-
Prescription medicine registrationActive ingredients: alectinib hydrochloride.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TECENTRIQ SC atezolizumab 1875 mg/15 mL solution for injection vial.
-
-
Australian public assessment report (AusPar)Polivy (polatuzumab vedotin) was approved for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma.
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Designation or determinationOrphan drug
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COLUMVI glofitamab (rch) 2.5 mg/2.5 mL concentrated solution for infusion vial.